Skip to main content

Diabetic Foot Ulcers (DFUs)

1
Pipeline Programs
4
Companies
6
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Lakewood-Amedex
Lakewood-AmedexFL - University Park
1 program
1
Antimicrobial agentPhase 21 trial
Active Trials
NCT07565506Not Yet Recruiting24Est. Dec 2026
Reprise Biomedical
Reprise BiomedicalMN - Plymouth
2 programs
Acellular Porcine-Derived Wound MatrixN/A1 trial
Miro3D Wound MatrixN/A2 trials
Active Trials
NCT06939673Recruiting20Est. Dec 2025
NCT07632001Recruiting180Est. May 2027
NCT06939686Recruiting30Est. Jul 2026
ConvaTec
ConvaTecNJ - Bridgewater
1 program
ConvaNioxN/A1 trial
Active Trials
NCT07438951Not Yet Recruiting102Est. Sep 2027
Skye Biologics
Skye BiologicsCA - El Segundo
1 program
E-GRAFT ™N/A1 trial
Active Trials
NCT06767501Recruiting100Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
Lakewood-AmedexAntimicrobial agent
ConvaTecConvaNiox
Reprise BiomedicalMiro3D Wound Matrix
Skye BiologicsE-GRAFT ™
Reprise BiomedicalMiro3D Wound Matrix
Reprise BiomedicalAcellular Porcine-Derived Wound Matrix

Clinical Trials (6)

Total enrollment: 456 patients across 6 trials

NCT07565506Lakewood-AmedexAntimicrobial agent

Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU

Start: Aug 2026Est. completion: Dec 202624 patients
Phase 2Not Yet Recruiting

A Study on the Efficacy and Safety of a Nitric Oxide Generating Dressing in the Treatment of Diabetes Related Foot Ulcers.

Start: Jul 2026Est. completion: Sep 2027102 patients
N/ANot Yet Recruiting

Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers

Start: Jun 2026Est. completion: May 2027180 patients
N/ARecruiting

Clinical Trial Evaluating an Amnion Membrane Allograft for Use in the Management of Non- Healing Diabetic Foot Ulcers Versus Standard Of Care

Start: Dec 2024Est. completion: Dec 2025100 patients
N/ARecruiting

Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

Start: Nov 2024Est. completion: Jul 202630 patients
N/ARecruiting
NCT06939673Reprise BiomedicalAcellular Porcine-Derived Wound Matrix

Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care

Start: Feb 2024Est. completion: Dec 202520 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 actively recruiting trials targeting 456 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.